The results from both tumor models support the conclusion that the RIPK3-driven necroptotic safety switch enhances the therapeutic efficacy of cancer cell–based therapies and promotes long-term immunity across different tumor models, thereby reinforcing the potential clinical applicability of this approach. Here, RIPK3 is linked to neoplasm.